Monkeypox is usually a self-limiting disease with symptoms lasting 2 to 4 weeks. Severe cases occur most often among children and are related to the degree of exposure to the virus, the patient's state of health, and the nature of complications. Underlying immune deficiencies may lead to poorer outcomes. Although smallpox vaccination was protective in the past, nowadays people under the age of 40 to 50 (depending on the country) may be more susceptible to monkeypox due to the cessation of smallpox vaccination campaigns around the world after the eradication of the disease.
Complications of monkeypox can include secondary infections, bronchopneumonia, sepsis, encephalitis, and infection of the cornea with consequent loss of vision. The extent to which an asymptomatic infection can occur is unknown. The fatality rate for monkeypox has historically ranged from 0 to 11% in the general population and has been higher among young children. In recent times, the fatality rate has fluctuated between 3 and 6%.
Historically, cases outside of Africa have been less common and are usually related to international travel or imported animals. Previous cases have been reported in Israel, the United Kingdom, K. Cases of monkeypox can sometimes be more serious, and some deaths have been reported in West Africa. Monkeypox can be an unpleasant disease; it causes fever, body aches, enlarged lymph nodes, and eventually smallpox, or painful, fluid-filled blisters on the face, hands, and feet.
One version of monkeypox is quite deadly and kills up to 10% of infected people. The version currently in England is softer. Its fatality rate is less than 1%. Usually, a case resolves in two to four weeks.
Usually, the disease lasts 2 to 4 weeks. In Africa, monkeypox has been shown to cause the death of up to 1 in 10 people who contract the disease. In Africa, monkeypox has been fatal in approximately 1 in 10 cases, with a higher likelihood of serious illness and death among children.